Keywords:
Cancer, Radiation therapy / Oncology, Oncology
Authors:
M. Grand, M. Berry, D. Forstner, S. Gillman, E. O'Reilly, P. Phan, L. Sutton, T. Vuong, K. Wong, S. Vinod; NSW/AU
DOI:
10.1594/ranzcr2018/R-0120
Results
The number of patients screened and recruited to clinical trials has increased from 2015-2017 (Figures 2 & 3).
The reduction in recruitment from 2016 to 2017 was due to a number of high recruiting trials closing for recruitment.
Analysis of the screening reports showed that over a 12 month period,
an additional 140 patients were identified in the screening reports that otherwise would have been missed.
With increased frequency of screening,
the analysis showed that on average,
an additional 17 patients were identified for screening per week.
The number of new patients being seen in clinic who had a MOSAIQ clinical trials screening assessment completed in MOSAIQ on average was 30% per year for the last 2 years.
The three most frequent primary reasons for non-eligibility in 2017 were clinician preference,
screening examinations and patient preference.
(Figure 4).
Specific reasons for non-eligibility for screened patients in 2017 were ‘test results out of range’ (e.g.
pathology becomes available after screening and patient does not meet eligibility criteria),
‘clinician recommended alternate treatment pathway’ (e.g.
patient is screened and then the most appropriate treatment pathway may be determined and the patient no longer meets eligibility criteria for the trial) and ‘patient declines to study schedule/procedures’ (e.g.
patient declines a procedure required for participation in a trial) (Figure 5).